Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US8951964B2 · kind B2 · utility
0Cited by
58References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 29, 2011 |
| Grant date | Feb 10, 2015 |
| Priority date | — |
| Expiry date | Mar 30, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.